Unavailable
Unavailable
Save time and jump to the most important pieces.
SC 13G/A - NAYA Biosciences, Inc. (0001417926) (Subject)
8-K - INVO Fertility, Inc. (0001417926) (Filer)
8-K - INVO Fertility, Inc. (0001417926) (Filer)
10-K - INVO Fertility, Inc. (0001417926) (Filer)
SARASOTA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:NAYA), formerly known as NAYA Biosciences, Inc., a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics, today confirmed it will begin trading under the new symbol "IVF" at the market open on April 28, 2025. The CUSIP number for the Company's common stock will remain unchanged. The symbol change follows the Company's announcement on April 14, 2025, regarding the strategic decision to separate its fertility and oncology businesses into distinct operations. "Our new Nasdaq ticker symbol of ‘IVF' reflect
Public company to operate under new name and concentrate on building, acquiring and operating fertility clinics and the distribution of FDA-cleared INVOcell device Private company to operate as NAYA Therapeutics and focus on clinical development of bifunctional antibodies SARASOTA, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc. (the "Company") (NASDAQ:NAYA), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition, and operation of fertility clinics, today announced its decision to separate its fertility and oncology operations. This strategic decision to separ
SARASOTA, Fla. and MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture ("IVC") fertility treatments, announced today that it will effect a 1-for-12 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on March 18, 2025. Commencing with the opening of trading on The Nasdaq Capital Market on March 18, 2025, the Company's common stock will trade on a post-split basis un